earnings
Pharma Direct Scaling: Core Transition Creates Durable Revenues (GDRX Q1 2026 Earnings Call)
GoodRx stabilized its first-quarter results through rapid expansion in its manufacturer-direct pricing programs, offsetting headwinds in its core prescription marketplace.